A prospective multicenter cohort study for treatment outcome, QOL, cost and cost-effectiveness of R-CHOP therapy alone and radiation combination therapy in untreated adult primary diffuse large B-cell lymphoma.
Not Applicable
- Conditions
- ntreated limited-stage DLBC
- Registration Number
- JPRN-UMIN000026684
- Lead Sponsor
- Clinical Hematology Study Group of National Hospital Organization
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1)Patients with central nervous/meningeal infiltration. 2)Patients with mental illness or impaired cognitive function at time of registration and with difficulty in writing and reading by themselves. 3)Patients with impaired vision at time of registration and with difficulty in writing and reading by themselves. 4)Patients for whom the attending doctor decided not suitable for participation in this study.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To clarify the cost-effectiveness in clinical practice of untreated limited-stage DLBCL. Net monetary benefit (NMB)
- Secondary Outcome Measures
Name Time Method To clarify the actual condition of treatment outcome, QOL, treatment-related cost and the cost-effectiveness in the limited-stage DLBCL. Incremental cost-effectiveness ratio (ICER),Overall survival (OS),Progression Free Survival (PFS), Overall response rate (ORR) of the best overall response in the first treatment period, Complete response rate (CRR) of the best overall response in the first treatment period,Quality of Life (QOL),Treatment-related cost.